The temporal progression aligns with the hypothesis that under EGFR-TKI selective pressure, a subclone of the original adenocarcinoma—harboring additional genetic alterations (e.g., RB1/TP53 loss)—acquired neuroendocrine features and proliferated as SCLC. The gene discussed is TP53; the disease is small cell lung carcinoma.